Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: Results of a phase II trial

Journal of Clinical Oncology

Volumn 15, Issue 8, 1997, Pages 2850-2857

  Tannehill, Scott P ^a   Mehta, Minesh P ^a   Larson, Marilyn ^a   Storer, Barry ^a   Pellet, John ^a   Kinsella, Timothy J ^a   Schiller, Joan H ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CISPLATIN; DEXAMETHASONE; ONDANSETRON; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ESOPHAGITIS; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0030797159     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.8.2850     Document Type: Article

References (34)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1996. CA Cancer J Clin 46:5-27, 1996
2. Cox JD: The role of radiotherapy in squamous, large cell, and adenocarcinoma of the lung. Semin Oncol 10:81-94, 1986
3. Perez CA: Dose-tumor response and survival studies in radiation therapy of non-small cell lung cancer. Chest 89:345-346, 1986
4. Dillman RO, Seagren SL, Propert KJ, et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940-945, 1990
5. Sause WR, Scott C, Taylor S, et al: RTOG 8808/ECOG 4588: Preliminary analysis of a phase III trial in regionally advanced unresectable non-small cell lung cancer with minimum three year follow-up. Int J Radiat Oncol Biol Phys 32:196, 1995 (suppl 1, abstr 111)
6. Le Chevlaier T, Arriagada R, Tarayre M, et al: Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. J Natl Cancer Inst 84:58, 1992 (letter)
7. Schaake-Koning C, Van den Bogaert W, Dalesio O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 326:524-530, 1992
8. Lee J, Scott C, Komaki R, et al: Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell-lung cancer: Radiation Therapy Oncology Group protocol 91-06. J Clin Oncol 14:1055-1064, 1996
9. Langer C, Curran W, Keller S, et al: Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiation. Cancer J Sci Am 2:99-105, 1996
10. Sause WT, Scott C, Taylor S, et al: Phase II trial of combination chemotherapy and irradiation in non-small-cell lung cancer, Radiation Therapy Oncology Group 88-04. Am J Clin Oncol 15:162-167, 1992
11. Capizzi RL: Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): Clinical experience. Semin Oncol 21:8-15, 1994 (suppl 1)
12. van der Vijgh WJF, Peters GJ: Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): Preclinical aspects. Semin Oncol 21:2-7 1994 (suppl 1)
13. Yuhas JM, Storer JB: Differential chemoprotection of normal and malignant tissues. J Natl Cancer Inst 42:331-335, 1979
14. Treskes M, Nijtmans LGJ, Fichtinger-Schepman AMJ, et al: The modulating agent amifostine and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate. Biochem Pharmacol 43:1013-1019, 1992
15. Turrisi AT, Glover DJ, Hurwitz S, et al: Final report on the phase I trial of single dose amifostine (S-2-[3-aminopropylamino]-ethylphosphorothioic acid). Cancer Treat Rep 70:1389-1393, 1986
16. Kemp G, Rose P, Lurain J, et al: Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-related toxicities: Results of a randomized controlled trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101-2112, 1996
17. Liu T, Liu Y, He S, et al: The use of radiation with or without amifostine in advanced rectal cancer. Cancer 69:2820-2825, 1992
18. Schiller JH, Storer B, Berlin J, et al: Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: A report of high response rates and prolonged survival. J Clin Oncol 14:1913-1921, 1996
19. Beahrs OH, Henson DE, Hutter RVP, et al: Manual for Staging of Cancer (ed 4): American Joint Committee on Cancer. Philadelphia, PA, Lippincott, 1992, pp 115-119
20. McDonald S, Meyerowitz C, Smudzin T, et al: Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction. Int J Radiat Oncol Biol Phys 29:747-754, 1994
21. McDonald S, Meyerowitz C, Smudain T, et al: Amifostine preserves salivary gland function during irradiation of the head and neck. Eur J Cancer 31:415, 1995 (suppl 5, abstr)
22. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Soc 53:457-481, 1958
23. Cox JD, Stetz J, Pajak TP: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341-1346, 1995
24. Tannehill SP, Mehta MP: Amifostine and radiation therapy: Past, present and future. Semin Oncol 23:69-77 1996 (suppl 8)
25. 35S-labeled WR-2721 in normal and malignant tissues of the mouse. Radiat Res 68:284-291, 1976
26. Yuhas JM: Active versus passive absorption kinetics as the basis for selective protection of normal tissue by S-2-[3-aminopropylamino]-ethylphosphorothioic acid. Cancer Res 40:1519-1524, 1980
27. Sculier JP, Klastersky J, Giner V, et al: Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 12:353-359, 1994
28. Roach M, Gandara DR, Yuo H-S, et al: Radiation pneumonitis following combined modality therapy for lung cancer: Analysis of prognostic factors. J Clin Oncol 13:2606-2612, 1995
29. Gandara R, Crowley J, Livingston RB, et al: Evaluation of cisplatin intensity in metastatic non-small cell lung cancer: A phase in study of the Southwest Oncology Group. J Clin Oncol 11:873-878, 1993
30. Klastersky J, Sculier J, Ravez P, et al: A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Oncol 4:1780-1786, 1986
31. Buntzel J, Glatzel M, Kuttner K, et al: Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head and neck cancer. Ethyol Investigators Meeting: Improving the Therapeutic Index in Cancer Therapy, Denver, CO, May 16, 1997
32. Betticher D, Anderson H, Ranson M, et al: Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: A randomised phase II study. Br J Cancer 72:1551-1555, 1995
33. Wadler S, Beitler J, Rubin JS, et al: Pilot trial of cisplatin, radiation and WR2721 in carcinoma of the uterine cervix: A New York Gynecologic Oncology Group study. J Clin Oncol 11:1511-1516, 1993
34. Byhardt RW, Scott CB, Ettinger DS, et al: Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer: Results of Radiation Therapy Oncology Group 90-15. Cancer 75:2337-2344, 1995